Managers who silence whistleblowers ‘will never work in NHS again’, vows Streeting
Exclusive: Shadow health secretary discusses plans for waiting lists and patient safety if Labour wins election
Related Articles
No RCC Recurrence in Patients Treated With Adjuvant Neoantigen Vaccine
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.
FGFR2 Mutations and IDH1 Real-World Data Suggests Caution with Immunotherapy in Specific mBTC
Explore the latest findings from a real-world data analysis on the effectiveness of immunotherapy in treating metastatic biliary tract cancer (mBTC) with spe…
For how long has this problem been there?
One of the most frequent questions asked by patients with monoclonal gammopathies is “Doctor, how long has this problem been there?” To this question, answ
Cancer scientist builds on groundbreaking immunity discovery
A renowned scientist @OSUCCC_James is building on a groundbreaking discovery that may lead to new treatments for cancer and inflammation.
Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia
Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.
Ziftomenib Treats Aggressive Subtypes of Acute Myeloid… : Oncology Times
An abstract is unavailable.
Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML
Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.
Tafasitimab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase…
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval – Oncology Nurse Advisor
The active ingredient in Journavx is suzetrigine, a sodium channel blocker.
